STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA. · 2011
Read STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. by Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3140523.txt.
Introduction
Andrea Bonetto and colleagues traced cancer weight loss to a single gene switch in muscle in a 2011 paper in PLoS ONE. Patients with wasting lose muscle despite eating, and the loss tracks with high blood levels of an immune signal and of emergency proteins. The team studied mice with tumours causing moderate and severe wasting.
Wasted muscle switched on one master control pathway strongly in both stages, and its target genes rose sharply. Surprisingly, muscle itself was making large amounts of the emergency proteins normally blamed on the liver, fed by amino acids freed as muscle broke down. Adding the immune signal to cultured muscle cells reproduced the effect. The pathway thus links the immune alarm, the blood protein surge, and muscle loss in one chain.
Catalog record
| CREATOR | Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia By Andrea Bonetto, Tufan Aydogdu, Noelia Kunzevitzky, Denis C. Guttridge, Sawsan Khuri, Leonidas G. Koniaris, Teresa A. Zimmers, Gianni Parise Published in: PLoS ONE DOI: 10.1371/journal.pone.0022538 ABSTRACT Background Cachexia, or weight loss despite adequate nutrition, significantly impairs quality of life and response to therapy in cancer patients. In cancer patients, skeletal muscle wasting, weight loss and mortality are all positively associated with increased serum cytokines, particularly Interleukin-6 (IL-6), and the presence of the acute phase response. Acute phase proteins, including fibrinogen and serum amyloid A (SAA) are synthesized by hepatocytes in response to IL-6 as part of the innate immune response. To gain insight into the relationships among these observations, we studied mice with moderate and severe Colon-26 (C26)-carcinoma cachexia. Methodology/Principal Findings Moderate and severe C26 cachexia was associated with high serum IL-6 and IL-6 family cytokines and highly similar patterns of skeletal muscle gene expression. The top canonical pathways up-regulated in both were the complement/coagulation cascade, proteasome, MAPK signaling, and the IL-6 and STAT3 pathways. Cachexia was associated with increased muscle pY705-STAT3 and increased STAT3 localization in myonuclei. STAT3 target genes, including SOCS3 mRNA and acute phase response proteins, were highly induced in cachectic muscle. IL-6 treatment and STAT3 activation both also induced fibrinogen in cultured C2C12 myotubes. Quantitation of muscle versus liver fibrinogen and SAA protein levels indicates that muscle contributes a large fraction of serum acute phase proteins in cancer. Conclusions/Significance These results suggest that the STAT3 transcriptome is a major mechanism for wasting in cancer. Through IL-6/STAT3 activation, skeletal muscle is induced to synthesize acute phase proteins, thus establishing a molecular link between the observations of high IL-6, increased acute phase response proteins and muscle wasting in cancer. These results suggest a mechanism by which STAT3 might causally influence muscle wasting by altering the profile of genes expressed and translated in muscle such that amino acids liberated by increased proteolysis in cachexia are synthesized into acute phase proteins and exported into the blood. INTRODUCTION Cachexia, or progressive wasting of fat and skeletal muscle despite adequate nutrition, is a pervasive and devastating complication of cancer [1], [2], [3]. Cachexia afflicts more than half of all cancer patients and results in weakness, diminished quality of life, poor response to therapy, and susceptibility to illness. Moreover, cachexia itself is responsible for 25–30% of all cancer-related deaths [1], [2]. Currently, there are no approved, effective treatments for muscle wasting in cancer. Clinically, cancer cachexia is defined as weight loss of at least 5% in the presence of underlying illness with associated muscle weakness, fatigue, anorexia, low lean body mass and abnormal biochemistry, including increased inflammation, anemia and low serum albumin. Weight loss of 5%, 10% or 15% total body weight is referred to as mild, moderate or severe cachexia, respectively, and both weight loss and the rate of weight loss correlate positively with mortality [4]. The etiology of cachexia is multi-factorial. Although a subset of patients experience early satiety and anorexia, studies have demonstrated that nutritional intake in cachectic patients should be sufficient to maintain body weight, but they lose weight regardless [5]. As well, cachectic patients can be hypo-, normo-, or hyper-metabolic with respect to resting energy expenditure, suggesting that alterations of metabolic rate alone cannot be responsible for the observed loss of body mass [2]. Furthermore, tumor competition for metabolic fuels is an unsatisfactory explanation of cachexia, both because pinpoint tumors can produce cachexia and because human tumors of 500 g or larger do not necessarily induce wasting [6]. The systemic metabolic derangements noted in cancer cachexia are also observed with other forms of systemic inflammation [7]. Cytokines, including Tumor Necrosis Factor (TNF)/cachectin, interleukin (IL)-1α, IL-1β, interferon-γ, and IL-6 have been implicated in cachexia both through experimental manipulation in mouse models and by association of serum levels in patients with cachexia [6], [7]. IL-6 is a multifunctional cytokine involved in a variety of host defenses and pathological processes [8]. Others and we have shown that IL-6 administration to mice is sufficient to induce wasting of muscle and fat stores and in the most severe cases, ultimately death [9], [10], [11], [12], [13], [14]. As well, IL-6 plays a substantial role in inducing cachexia in mice bearing the colon-26 cancer cell line and the uterine cancer line, Yomoto, as administration of IL-6 blocking agents reduce muscle wasting in those models [15], [16], [17], [18]. Serum IL-6 is a sensitive predictor of weight loss, including in patients with advanced small cell lung cancer [19] and colon cancer [20]. IL-6 and other gp130 ligands such as LIF and CNTF are thought to mediate cachexia through a combination of anorexia, lipid catabolism, insulin resistance, and effects on protein synthesis and degradation. However, the molecular pathways regulated by IL-6 in skeletal muscle that lead to muscle wasting are unknown. IL-6 acts on cells by binding the IL-6 receptor α-chain (IL-6Rα), also known as gp80, either in its membrane-bound or soluble form, inducing dimerization of gp130 and activation of its associated Janus kinases (JAKs), which tyrosine phosphorylates gp130 [21]. These events result in the activation of two major signaling pathways, STAT3, and the mitogen-activated protein kinase (MAPK/ERK) cascade. STAT3 activation by tyrosine phosphorylation leads to dimerization and nuclear translocation, DNA binding and modulation of gene expression. In cooperation with c-Jun and various forms of the transcription factor CAAT enhancer-binding protein (C/EBP), IL-6 signaling through STAT3 up-regulates acute phase response protein gene expression in the liver. The acute phase response is a generalized response of the innate immune system, consisting of some 40 genes up-regulated up to several thousand-fold upon stimulation [22]. Tisdale and Fearon with co-workers have linked cancer cachexia with persistent elevations in acute phase response proteins in serum [23], [24], [25]. Approximately 50% of all cancer patients demonstrate increased serum acute phase response proteins at the time of cancer diagnosis, and the percentage of cancer patients with an elevated serum acute phase response increases with disease burden and stage [24], [26]. Elevated levels of fibrinogen are observed in many malignancies, including lung and melanoma, and increased expression correlates with a bleak outcome [27], [28]. Current models posit that tumor and host derived factors induce proteolysis in order to fuel a chronic hepatic acute phase response. Production of acute phase response proteins in the liver requires catabolism of structural proteins in skeletal muscle as a source of amino acids. Given the differences in amino acid utilization in muscle proteins versus acute phase reactants, up to 2.6 g of muscle protein or 12 g of muscle tissue may be wasted to synthesize 1 g acute phase response proteins [29]. We sought to determine potential relationships between elevated cytokines, the acute phase response and wasting in cancer. Here we report characterization of the serum cytokines and the muscle transcriptome in the colon-26 adenocarcinoma model of cancer cachexia. We provide evidence of STAT3 activation, target gene expression and the acute phase response in both liver and skeletal muscle in these mice, providing a molecular link between these observed phenomena. RESULTS Colon26 model of cancer cachexia Implantation of colon-26 (C26) adenocarcinoma cells into Balb/c or CD2F1 mice is a classic model